1.. Introduction {#s1}
================

Ca^2+^ entry through T-type channels was reported to have two main roles, one related to cell excitability and the other to the stimulation of a range of Ca^2+^-dependent biological events.^[@CVQ379C1]--[@CVQ379C3]^ In ventricular cardiomyocytes, both Ca~v~3.1 and Ca~v~3.2 channel subunits are responsible for *I*~CaT~, and the pattern of expression of these channels varies with the stage of heart development.^[@CVQ379C4]--[@CVQ379C6]^ The reappearance of *I*~CaT~ in adult cardiomyocytes was reported, in association with several aetiologies of ventricular hypertrophy.^[@CVQ379C3]^ However, little is known about the mechanism involved in the regulation of T-type channel expression, and the *I*~CaT~-dependent Ca^2+^ signalling pathway remains to be explored.

It has repeatedly been demonstrated that Ca~v~3.1 and Ca~v~3.2 are regulated differently and have different cellular functions. Consistent with this observation, mice lacking Ca~v~3.1 have a cardiac phenotype different from that of mice lacking Ca~v~3.2 and, similarly, mice overexpressing the Ca~v~3.1 gene have a response to hypertrophic stimuli very different from that of mice overexpressing the Ca~v~3.2 gene.^[@CVQ379C7],[@CVQ379C8]^ However, the role of *I*~CaT~ in the development of cardiac hypertrophy remains a matter of debate, as does the identity of the channel subunit involved. Indeed, Chiang *et al*.^[@CVQ379C7]^ reported that cardiac hypertrophy was associated with Ca~v~3.2 expression (but not with Ca~v~3.1 expression), whereas Nakayama *et al*.^[@CVQ379C8]^ described an anti-hypertrophic role for Ca~v~3.1. Our previous work with an *in vivo* model provided evidence that the pathological re-expression of Ca~v~3.1 and, to a lesser extent, Ca~v~3.2 channels was independent of cardiac hypertrophy *per se*, and we suggested that *I*~CaT~ might be associated with end-stage organ damage during cardiac disease.^[@CVQ379C9]^ Consistent with this hypothesis, the use of mibefradil, an *I*~CaT~ antagonist, was shown to improve survival in a rat model of chronic heart failure such as sudden death and fibrillation, suggesting that *I*~CaT~ blockade might have a beneficial impact on cardiac diseases.^[@CVQ379C10],[@CVQ379C11]^

Aldosterone is known to be involved in the development of cardiac hypertrophy and failure, and was described as participating in electrophysiological remodelling in ventricular myocytes, increasing both L-type Ca^2+^ current (*I*~CaL~) and *I*~CaT~.^[@CVQ379C12],[@CVQ379C13]^ In this study, we used aldosterone to investigate the mechanisms involved in channel gene expression, to identify the signalling pathways triggered by *I*~CaT~-generated Ca^2+^ influx, and to determine the cellular impact of *I*~CaT~-generated Ca^2+^ signalling in cardiomyocytes. We found that aldosterone-dependent *I*~CaT~-generated Ca^2+^ signalling induced negative feedback on cAMP-response element-binding protein (CREB) via protein phosphatase 2A (PP2A). Through its targeting of PP2A, *I*~CaT~ increased pro-apoptotic markers and cell death. These findings implicate *I*~CaT~ in the regulation of CREB-dependent gene expression and *I*~CaT~/PP2A/CREB signalling in promoting apoptosis.

2.. Methods {#s2}
===========

2.1. Animals and culture conditions {#s2a}
-----------------------------------

Animals were cared for and used in accordance with the European convention for the protection of vertebrates used for experimental purposes, and institutional guidelines no. 86/609/CEE 24 November 1986 and conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication no. 85-23, revised 1996). Primary cultures of ventricular myocytes were each prepared from hearts of 10 1-day-old male Wistar rats (Charles Rivers, France) as described previously.^[@CVQ379C9]^ Following tissue digestion, cells were plated (low density, 1 h at 37°C) in normal growth medium to isolate cardiomyocytes from adherent cells. Non-adherent cells were collected, plated on new dishes, and maintained in serum-free DMEM supplemented with medium 199 (4:1) and 1 µM cytosine β-[d]{.smallcaps}-arabinofuranoside (Sigma), to prevent proliferation of residual non-myocytes. Cells were exposed to aldosterone or pre-treated with antagonists or inhibitors prior to addition of aldosterone. The antagonists or inhibitors used were RU 38486 spironolactone, mibefradil, flunarizine, fluoxetine, or nifedipine all from Sigma, FK506, or okadaic acid (OA) from Alexis Biochemicals (San Diego, CA, USA) and dexamethasone from Sigma.

The hypertrophic model was described elsewhere.^[@CVQ379C9]^ Briefly, adult male Wistar rats were subjected to abdominal aortic stenosis for 6 (AS6) or 12 weeks (AS12) and controls were age-matched sham-operated rats (Ctl6 and Ctl12). The left ventricles were isolated, rapidly frozen, and stored at −80°C.

2.2. Electrophysiological recordings {#s2b}
------------------------------------

Ca^2+^ currents were recorded by whole-cell patch-clamp technique, at room temperature (22--24°C). The fire-polished pipettes used had a resistance of 1--3 MΩ when filled with pipette solution: 10 mM CsCl, 120 mM Cs-aspartate, 3 mM MgCl~2~, 10 mM HEPES, 15 mM EGTA, 1.8 mM CaCl~2~, 10 mM glucose, 3.6 mM creatine phosphate, 5 mM MgATP, 0.2 mM Tris-GTP, pH 7.2, adjusted with CsOH. Ca^2+^ currents were recorded in an external solution containing: 135 mM TEA-Cl, 1 mM MgCl~2~, 10 mM CaCl~2~, 10 mM HEPES, 10 mM glucose, 3 mM 4--aminopyridine, 20 mM CsCl, 0.03 mM tetrodotoxin, pH 7.4, adjusted with CsOH. Additional details of data recording were reported elsewhere.^[@CVQ379C5]^

2.3. Transfection and luciferase assay {#s2c}
--------------------------------------

The 3 kb region upstream from *cacna1g* was isolated from Wistar rat genomic library (λ DASH II, Stratagene) and inserted into the luciferase reporter pGL3-basic vector (Promega, Madison, WI, USA) as described previously.^[@CVQ379C14]^ The resulting plasmid was used to generate chimeric pGL promoter/luciferase constructs (pGL4100--pGL4600). The GRE1 mutant (853 bp upstream from the translation start site) resulted from a point mutation generated in pGL4400 by PCR with 5′TGGAAGGGCGTCC(T)A(C)TGGA3′ used as the primer. Neonatal myocytes were cotransfected using luciferase construct and pSVβgal (Promega) with FuGENE 6 (Roche, Indianapolis, NI, USA). Luciferase and β-galactosidase activities were determined in a related reporter assay system (Promega). All experiments were performed on at least three cultures set up in triplicate.

2.4. RNA isolation and mRNA quantification {#s2d}
------------------------------------------

Total RNA samples were prepared from ventricular tissues using Trizol (Invitrogen). The Ca~v~3.1, Ca~v~3.2, cyclophylin primers, and quantitative RT--PCR procedures have been described elsewhere.^[@CVQ379C5],[@CVQ379C15]^ Briefly, quantitative RT--PCR was performed with a normalized RNA aliquot (1 µg) and a known amount of cRNA internal control (2.5 × 10^6^ molecules). The internal control differed from the target counterpart by only one restriction site. PCR was performed with a trace amount of ^32^P-labelled 5′ primer. The number of copies per micrograms of total RNA was calculated using the following equation: \[Internal control weight/(size in nucleotides × 330)\] × 6.02 × 10^23^, and from the relationship \[molecules cRNA control/cpm cRNA control\] × cpm target = target molecules per normalized RNA aliquot.

2.5. Protein extraction and western blot analysis and phosphatase activity assay {#s2e}
--------------------------------------------------------------------------------

The preparation of cytosolic, nuclear, and total extracts were described elsewhere.^[@CVQ379C14]^ Antibodies were glucocorticoid receptor (GR), Bcl-x~L~ Bcl-x~S~, Bcl-2 (Santa Cruz Biotechnology, CA, USA), total CREB, Ser-133-phosphorylated CREB (pCREB), caspase 9 (Cell Signaling Technology, MA, USA), which detects the pro-caspase 9 as well as the cleaved fragment of caspase 9, catalytic subunit of PP1 (Santa Cruz Biotechnology), PP2AC, and PP2B (Cell Signaling Technology). Actin (Santa Cruz) was used for normalization. Protein bands were visualized with the Lumi-light^plus^ blotting Kit (Roche) and analysed with Gene Tools from Syngen (Cambridge, UK). The activity of PP2A was measured with the Ser/Thr phosphatase assay system (Promega). Phosphatase activity was calculated as the rate of Pi release from pre-phosphorylated peptide and normalized with respect to basal levels (sample without phosphopeptide).

2.6. Flow cytometry {#s2f}
-------------------

For each treatment, cells were collected after digestion with trypsin. Samples from each cell suspension were stained with fluorescein isothiocyanate (FITC)-conjugated annexin V; propidium iodide (PI) exclusion assay (PI-Pharmingen) was carried out according to the manufacturer\'s protocol. For each sample, 30 000 cells were analysed on an FACSCalibur machine, with CELLQuest software (Becton Dickinson, Franklin Lakes, NJ, USA). Counts are expressed as a percentage of the total number of cells counted.

2.7. Statistical analysis {#s2g}
-------------------------

Data are expressed as means ± SEM (*n* ≥ 3). The statistical significance of differences between groups was estimated by one-way ANOVA, followed by Dunnett\'s test or two-way ANOVA, followed by Bonferroni\'s test. Differences were considered significant if *P* \< 0.05.

3.. Results {#s3}
===========

3.1. Aldosterone increases Ca~v~3.1-related current {#s3a}
---------------------------------------------------

Cultures of ventricular myocytes treated with aldosterone for 48 h displayed an increase in *I*~CaT~ current density (5.7 ± 0.5 pA/pF *n* = 15 vs. 3.6 ± 0.3 pA/pF *n* = 8 in the control, *P* \< 0.01; *Figure [1](#CVQ379F1){ref-type="fig"}A* and *B*) that was not associated with changes in activation or in steady-state inactivation parameters (*Figure [1](#CVQ379F1){ref-type="fig"}C*). The nature of the Ca~v~3.X-related current induced by aldosterone was determined on the basis of the Ni^2+^ sensitivity of *I*~CaT~ (*Figure [1](#CVQ379F1){ref-type="fig"}D*). The Ni^2+^ dose--response in control conditions indicated that *I*~CaT~ was blocked in the monophasic mode, with an IC~50~ of 300 µM, whereas, in aldosterone-treated myocytes, *I*~CaT~ was blocked in the biphasic mode, with IC~50~ values of 1.5 and 300 µM (*Figure [1](#CVQ379F1){ref-type="fig"}D*), corresponding to the sensitivities described for Ca~v~3.2- and Ca~v~3.1-related currents, respectively.^[@CVQ379C16],[@CVQ379C17]^ The relative contributions of these currents were assessed from the Ni^2+^ dose--response relationship, and we found that Ca~v~3.2 and Ca~v~3.1 contributed 20 and 80% of the total current, respectively. These relative contributions of functional Ca~v~3.X channels correspond to observations reported in pathological conditions.^[@CVQ379C9]^ Figure 1Aldosterone increases principally Ca~v~3.1-generated T-type calcium current. (*A*) Typical recordings are shown for control (Ctl) and aldosterone treatment (Aldo, 1 µM). (*B*) *I*~CaT~ density--voltage relationships in Ctl (*n* = 8) and Aldo (*n* = 15). (*C*) Voltage-dependent activation (squares) and steady-state inactivation (circles) curves. Activation: *V*~0.5~ = −27.0 ± 2.6 mV, *k* = 5.8 ± 0.5 mV for Ctl (*n* = 6); *V*~0.5~ = −31.4 ± 0.4 mV, *k* = 4.8 ± 0.1 mV for Aldo (*n* = 11). Inactivation *V*~0.5~ = −63.7 ± 1.5 mV, *k* = −4.3 ± 0.2 mV for Ctl (*n* = 6); *V*~0.5~ = −60.4 ± 0.5 mV, *k* = −4.7 ± 0.1 mV for Aldo (*n* = 8). (*D*) Dose--response curves for Ni^2+^ on *I*~CaT~ recorded from a holding potential of −100 mV to a test pulse of −20 mV. *n* = 5--10 cells for each Ni^2+^ concentration. For Ctl, the IC~50~ is 300 µM. For aldosterone, two IC~50~ values were determined: 1.5 and 300 µM. \**P* \< 0.05 vs. Ctl.

3.2. Aldosterone increases transcription of the Ca~v~3.1 gene by activating the GR {#s3b}
----------------------------------------------------------------------------------

Quantitative RT--PCR showed that Ca~v~3.1 and Ca~v~3.2 mRNA levels were higher (by factors of 2.4 and 1.4, respectively) in aldosterone-treated cells than in control cells (*Figure [2](#CVQ379F2){ref-type="fig"}A*). These results contrast with those of Lalevée *et al.*^[@CVQ379C13]^ who found that aldosterone-induced *I*~CaT~ was associated with an increase in the amount of Ca~v~3.2 mRNA (up to 410%) and a non-significant increase in the Ca~v~3.1 mRNA level. This discrepancy is probably due to the use of an inappropriate normalization marker, cyclophilin, which is repressed in aldosterone-treated cells, and the use of primers that do not recognize the relevant isoform (data shown and discussed in [Supplementary material online, *FigureS1*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq379/DC1)). Thereafter, we have focused our study on the regulation of Ca~v~3.1 gene expression. Figure 2Aldosterone increases Ca~v~3.1 expression by activating GRs. (*A*) Quantitative RT--PCR of Ca~v~3 subunits in cells treated by 1 µM aldosterone for 24 h, *n* = 5 for each point. (*B*) Increase in Ca~v~3.1 mRNA levels over time, *n* = 4 performed in duplicate for each point. (*C*) *cacna1g* promoter activity. *Age*I (A), *Bgl*II (B), *Hin*dIII (H), *Stu*I (St), *Xba*I (Xb) and *Xho*I (X). Mean relative luciferase activity (RLA) units ± SE. (*D*) Effect of spironolactone (spi, 10 µM) and RU 38486 (RU, 10 µM) on pGL4400-transfected cells. *n* = 3 performed in triplicate. (*E*) Identification of the functional GRE in *cacna1g* promoter. Cells were transfected with either wild-type pGL4400 (WT) or mutated pGL4400-GRE1 (mGRE1) and exposed to 1 µM aldosterone or 10 µM dexamethasone (Dex), *n* = 3 performed in triplicate. (*F*) Nuclear translocation of GRs in aldosterone-treated cells. Western blots were performed with cytosolic (S1, *n* = 3) and nuclear extracts (NE, *n* = 3) performed in triplicate. \**P* \< 0.05, ns vs. Ctl.

The amount of Ca~v~3.1 mRNA increased in aldosterone-treated cells, reaching a plateau 9h after the beginning of treatment (*Figure [2](#CVQ379F2){ref-type="fig"}B*). Cycloheximide treatment did not prevent aldosterone-induced increases in mRNA levels during the first hour ([Supplementary material online, *FigureS2*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq379/DC1)), suggesting that aldosterone activated pre-existing regulatory factors. However, protein synthesis was required for a sustained effect of aldosterone, since the Ca~v~3.1 mRNA amount gradually declined after the first hour of aldosterone plus cycloheximide treatment. The effect of the pre-existing transcriptional factor was no longer visible after 9 h of treatment.

We further assessed *cacna1g* regulation by investigating promoter activity through unidirectional deletions and point mutations. Aldosterone treatment induced an increase in promoter activity, which was maximal for sequences up to 1.5 kb long (pGL4400) (*Figure [2](#CVQ379F2){ref-type="fig"}C*). Aldosterone had a dose-dependent effect on Ca~v~3.1 upregulation, and we found that when compared with control, 1 µM induced an 87% increase of pGL4400 activity and 0.1 µM only 20% increase of pGL4400 activity ([Supplementary material online, *FigureS3*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq379/DC1)).

Treatment with the GR antagonist RU 38486 almost completely turned off the transcription of pGL4400 (and pGL4600, data not shown) in both aldosterone-treated and untreated cells (*Figure [2](#CVQ379F2){ref-type="fig"}D*). In contrast, the mineralocorticoid receptor (MR) antagonist spironolactone simply decreased the level of transcription. Several putative glucocorticoid response elements (GREs) are present in pGL4400.^[@CVQ379C14]^ Mutations in GRE1 abolished aldosterone-induced transcription of the Ca~v~3.1 gene, *cacna1g* (*Figure [2](#CVQ379F2){ref-type="fig"}E*), but did not alter basal levels of transcription or the levels of transcription induced by a synthetic glucocorticoid analogue, dexamethasone. Consistent with these findings, the rapid (10 min) translocation of GR from the cytosol to the nuclear compartment (*Figure [2](#CVQ379F2){ref-type="fig"}F*) was observed in aldosterone-treated cells, supporting the role of GR in the genomic response of aldosterone. After 2 h of incubation with aldosterone, the amount in cytosolic GR returned to control levels, probably due to *de novo* GR synthesis. These findings are consistent with the involvement of pre-existing regulatory factors and the need for *de novo* synthesis for sustained increases in mRNA levels.

3.3. *I*~CaT~ modulates *cacna1g* expression and CREB activation {#s3c}
----------------------------------------------------------------

To test the hypothesis that *I*~CaT~ is likely to play a role in the control of gene expression, we investigated the effect of the *I*~CaT~ blockers mibefradil, fluoxetine, and flunarizine^[@CVQ379C18]--[@CVQ379C20]^ on *cacna1g* expression (*Figure [3](#CVQ379F3){ref-type="fig"}A*). During the exponential phase of mRNA accumulation (until 6 h---*Figure [2](#CVQ379F2){ref-type="fig"}B*), Ca^2+^ current blockers had no effect on the amount of Ca~v~3.1 mRNA (*Figure [3](#CVQ379F3){ref-type="fig"}A*). However, during the plateau phase (9 h), Ca~v~3.1 mRNA levels were higher with aldosterone plus mibefradil (AM) or flunarizine (AFluna) \[or fluoxetine (AFluo), data not shown\] than with aldosterone alone. Blocking *I*~CaL~ with nifedipine had no additional effect. The aldosterone-induced increase in *I*~CaT~ density triggered negative feedback control over *cacna1g* expression that was confirmed by the stronger promoter activity observed in pGL4400-transfected cells exposed to AM than in transfected cells exposed to aldosterone alone (*Figure [3](#CVQ379F3){ref-type="fig"}B*). We then focused on the transcription factors regulated by *I*~CaT~-generated Ca^2+^ influx. As GR can interact with the CREB,^[@CVQ379C21]^ we investigated the effect of *I*~CaT~ blockade on GR translocation and CREB activation. GR translocation was unchanged in cells exposed to AM or AFluna ([Supplementary material online, *FigureS4*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq379/DC1)). Aldosterone induced a rapid increase in Ser133-phosphorylated CREB protein levels in the nucleus (*Figure [3](#CVQ379F3){ref-type="fig"}C*), and aldosterone-induced CREB activation was doubled by *I*~CaT~ blockade (*Figure [3](#CVQ379F3){ref-type="fig"}D*). The level of total CREB remained stable within these culture conditions (data not shown). Figure 3*I*~CaT~ blockade upregulates *cacna1g* expression and increases pCREB protein levels. (*A*) Effect of *I*~CaT~ blockade on the increase in Ca~v~3.1 mRNA levels over time. Cells were cultured with 1 µM mibefradil (CM), mibefradil plus 1 µM aldosterone (AM), mibefradil plus aldosterone and 5 µM nifedipine (AMN) or with aldosterone, and 10 µM flunarizine (AFluna), for the times indicated. *n* = 4 for each condition, \**P* \< 0.05 vs. aldosterone. (*B*) Effect of 1 µM mibefradil on pGL4400 activity, *n* = 3 performed in triplicate. (*C*) Nuclear translocation of phosphorylated CREB. Western blots were performed with nuclear extracts from cells subjected to short-term aldosterone treatment. *n* = 4 performed in duplicate. (*D*) Effect of *I*~CaT~ blockade on CREB activation. Western blots were performed with total protein extracts from cells treated for 24 h. *n* = 3 performed in duplicate. (*E*) Phosphorylated CREB levels in the pathological model. Western blots were performed with total protein extracts from left ventricles of 6 (*n* = 4) or 12 (*n* = 6) weeks stenosed rats (AS6 and AS12) paired with sham-operated rats (Ctl6, *n* = 4 and Ctl12, *n* = 5). \**P* \< 0.05.

Finally, we used a rat model of abdominal aortic stenosis to examine the possible relationship between *I*~CaT~ and CREB phosphorylation in pathological conditions. We have previously shown that *I*~CaT~ only re-emerges after long-term stenosis, well after the establishment of compensated hypertrophy. Indeed, *I*~CaT~ was absent 6 weeks after the induction of stenosis and re-emerged after 12 weeks of stenosis.^[@CVQ379C9]^ We show here that CREB phosphorylation levels were increased in the 6-week stenosis group compared with the sham-operated group, whereas CREB phosphorylation was almost abolished in the 12-week stenosis group (*Figure [3](#CVQ379F3){ref-type="fig"}E*). Decrease in CREB phosphorylation was prevented in conditions in which *I*~CaT~ re-expression was diminished ([Supplementary material online, *FigureS5*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq379/DC1)).

3.4. *I*~CaT~ modulates CREB activation via PP2A {#s3d}
------------------------------------------------

Many signalling pathways are thought to control CREB phosphorylation status, depending on cell and physiopathological status.^[@CVQ379C22]^ We investigated the involvement of the serine threonine phosphatases 1, 2A, and 2B (PP1, PP2A, and PP2B), to identify the protein phosphatases modulating CREB activation during aldosterone treatment (*Figure [4](#CVQ379F4){ref-type="fig"}*). Cells were treated with the PP2B (calcineurin) inhibitor FK506 (1 µM) or with the PP2A inhibitor OA (5 nM) (*Figure [4](#CVQ379F4){ref-type="fig"}A*). OA treatment increased phosphorylated CREB levels in control and aldosterone-treated cells. In contrast, FK506 treatment prevented the aldosterone-induced increase in phosphorylated CREB levels but had no effect on these levels in control cells. Neither OA nor FK506 affected total CREB levels (data not shown). Figure 4*I*~CaT~ blockade decreases PP2A-induced CREB dephosphorylation. (*A*) Effect of PP2A and PP2B on CREB phosphorylation. Total proteins were extracted from cells exposed for 24 h to 1 µM FK506 (FK) or 5 nM okadaic acid (OA). *n* = 3 performed in duplicate. (*B*) Aldosterone increases PP2A--PP1 activities via *I*~CaT~ signalling. Total PP2A and PP1 activities were quantified in cells treated for 24 h with 1 µM aldosterone and 1 µM mibefradil or 5 µM fluoxetine (AM, AFluo) or *I*~CaT~ and *I*~CaL~ blockers (AMN); 12 nM OA blocked PP2A activity and 5 µM OA blocked PP2A and PP1 activities. Protein phosphatase inhibitor-2 (I-P1) blocked PP1 activity. PhosPep = 0.1 mM phosphopeptide alone. *n* = 3 performed in triplicate. \**P* \< 0.05.

PP2A and PP1 activities were determined *in vitro* for cardiomyocyte lysates and could be separated on the basis of sensitivity to OA concentration (*Figure [4](#CVQ379F4){ref-type="fig"}B*). In aldosterone-treated cells, total PP2A--PP1 activity was twice that in control cells, mostly due to an increase in PP2A activity. Indeed, 80 ± 5% of phosphatase activity was abolished by PP2A blockade (OA---12 nM). The aldosterone-induced increase in PP2A--PP1 activity was prevented by the *I*~CaT~ blockers. The small contribution of PP1 in aldosterone-treated cells was confirmed using an inhibitor of PP1, and its activation shown to depend on *I*~CaT~-generated Ca^2+^ signalling (*Figure [4](#CVQ379F4){ref-type="fig"}B*, *bottom panel*). Finally, we were unable to detect a significant difference in the amounts of the catalytic subunits of PP1, PP2A, and PP2B, under the different culture conditions tested ([Supplementary material online, *FigureS6*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq379/DC1)). Therefore, aldosterone-induced *I*~CaT~ upregulates the level of phosphatase activity through post-transcriptional regulation rather than changes in phosphatase gene expression.

3.5. *I*~CaT~ modulates cell-death markers via PP2A {#s3e}
---------------------------------------------------

An increase in PP2A activity was associated with cell death.^[@CVQ379C23]^ We investigated whether *I*~CaT~-induced PP2A activity might be involved in cardiomyocyte death (*Figure [5](#CVQ379F5){ref-type="fig"}*). An increase in activated caspase 9 levels occurred only 9 h after the start of the treatment (*Figure [5](#CVQ379F5){ref-type="fig"}A*) in parallel with a time-dependent effect of *I*~CaT~ blockade (*Figure [3](#CVQ379F3){ref-type="fig"}A*). At this time point, treatment with OA prevented the aldosterone-induced caspase 9 activation. Aldosterone also induced a switch between the Bcl-x~L~ and Bcl-x~S~ variants, which was prevented by the use of OA or OA plus mibefradil (*Figure [5](#CVQ379F5){ref-type="fig"}B*). These results indicated that the timing of PP2A activation was related to an increase in *I*~CaT~-generated Ca^2+^ influx. The relationship between *I*~CaT~ and the activation of pro-apoptotic markers was confirmed in cells treated for 24 h with aldosterone, in which the increase in caspase 9 and Bcl-x~S~ levels and the decrease in Bcl-2 levels were reversed by treatment with mibefradil or fluoxetine (*Figure [5](#CVQ379F5){ref-type="fig"}C*). Figure 5Aldosterone induces pro-apoptotic markers via PP2A. (*A*) Aldosterone-induced time-dependent activation of caspase 9. Cells exposed to 1 µM aldosterone were treated with 5 nM OA (A OA) for the time periods indicated. *n* = 3 performed in duplicate. (*B*) Aldosterone-induced increase in the Bcl-x~S~ variant via PP2A. Cells were exposed for 9 h to 1 µM aldosterone, together with 5 nM OA (A OA) or 1 µM mibefradil + 5 nM OA (AM OA). *n* = 3 performed in duplicate. (*C*) Effect of *I*~CaT~ blockers on the aldosterone-induced increase in apoptotic markers in cells treated for 24 h. *n* = 3 performed in duplicate. (*D*) Expression of apoptotic markers in the pathological model. Proteins were extracted from left ventricles of 6- and 12-week stenosed rats paired with control. Ctl6 and AS6 *n* = 4, Ctl12 *n* = 5 and AS12 *n* = 6. \**P* \< 0.05.

Finally, using a rat model of cardiac hypertrophy, we have shown in long-term stenosis (12 weeks treatment---AS12) that the levels of caspase 9 and Bcl-x~S~ markedly increased, whereas the reciprocal effect was seen on Bcl-2, when compared with the sham group (Ctl12) (*Figure [5](#CVQ379F5){ref-type="fig"}D*). Only the levels of Bcl-x~S~ increased during hypertrophy (6 weeks treatment---AS6 vs. Ctl6) or ageing (Ctl12 vs. Ctl6).

3.6. Aldosterone-induced *I*~CaT~ contributes to myocyte apoptosis and necrosis {#s3f}
-------------------------------------------------------------------------------

Apoptosis was quantified by FACS analysis after staining with annexin V-FITC and PI. As previously reported,^[@CVQ379C24]^ aldosterone induced cardiomyocyte apoptosis in cells treated for 24 h, as shown by flow cytometry (annexin V-stained cells, Q2 + Q4) (*Figure [6](#CVQ379F6){ref-type="fig"}A*). However, longer periods of exposure to aldosterone (48 h) increased the number of necrotic PI-stained cells (Q1) (*P* \< 0.05 vs. Q1 aldosterone 24 h), whereas no significant difference was found in the number of annexin V---or annexin V + PI-stained cells (Q2 + Q4) between 24 and 48 h of aldosterone exposure. Treatment with AM decreased the effect of aldosterone on cell death, as shown by smaller numbers of necrotic cells (*P* \< 0.05, Q1 AM vs. Q1 aldosterone 48 h) and apoptotic cells (*P* \< 0.05, Q2 + Q4 AM vs. Q2 + Q4 aldosterone 48 h). Treatment with AFluo also reduced the number of necrotic cells (*P* \< 0.05, Q1 AFluo vs. Q1 aldosterone 48 h) but did not significantly reduce the number of annexin V-stained cells (Q2 + Q4) vs. (Q2 + Q4) aldosterone 48 h. The use of nifedipine in addition to aldosterone plus mibefradil (AMN) enhanced the effect of AM reducing further the number of PI-stained cells (*P* \< 0.05, Q1 AMN vs. Q1 AM and Q1 AMN vs. Q1 aldosterone 48 h). In conclusion, the use of mibefradil with or without nifedipine reversed the effect of aldosterone on cell viability (*Figure [6](#CVQ379F6){ref-type="fig"}B*). Thus, aldosterone-dependent apoptosis and necrosis are induced by both *I*~CaT~ and *I*~CaL~. Figure 6*I*~CaT~ blockade reduces aldosterone-induced myocyte apoptosis and necrosis. (*A*) Representative graphs from flow cytometry analysis. Cells were treated for the indicated periods before annexin V-FITC/PI double staining. Q1 = annexin V-negative/PI-positive, Q2 = annexin V-positive/PI-positive, Q3 = annexin V-negative/PI-negative and Q4 = annexin V-positive/PI-negative. Annexin V and PI labelled pro-apoptotic and necrotic cells, respectively. (*B*) Cell viability from annexin V-negative/PI-negative stained cells. Clt and Aldo 48 h *n* = 6, Aldo 24 h and AMN *n* = 4, AM and AFluo *n* = 5. \**P* \< 0.05.

4.. Discussion {#s4}
==============

We have investigated the signalling pathway(s) of *I*~CaT~ and its implication in cardiomyocyte death. In this context, we have focused on the pathway(s) by which aldosterone upregulates Ca~v~3.1 expression to generate *I*~CaT~ and identified mechanisms involved in *cacna1g* expression.

We show here that, in neonatal cardiomyocytes, aldosterone-induced increase in *I*~CaT~ density results mostly from an increase in Ca~v~3.1 expression. The transactivation of *cacna1g* by GR was observed with either aldosterone or dexamethasone (1 µM), but aldosterone-activated GRs targeted a GRE (GRE1) that is different from those targeted by dexamethasone-activated GRs. The aldosterone-induced increase in *I*~CaT~-generated Ca^2+^ signalling led to molecular remodelling. Indeed, we found that aldosterone-induced CREB phosphorylation was altered by *I*~CaT~-generated Ca^2+^ signalling, likely resulting in a reduced transcription of CREB\'s target genes. *I*~CaT~-signalling also exerts a negative feedback regulation on *cacna1g* expression, which occurs only after exposure to aldosterone for 9 h, suggesting that functional channels are not present at the membrane before that time. While there is still insufficient evidence to infer the existence of a direct interaction between CREB and the GR-binding *cacna1g* promoter, it seems likely that the *I*~CaT~-induced decrease in *cacna1g* expression is due to a defect in CREB interference with the GR-binding activity of GRE1. Further investigations of this issue are required.

We also found that the decrease in phosphorylated CREB levels was mediated by an *I*~CaT~-induced increase in PP2A and, to a lesser extent, to PP1 activities. However, PP2B exerts opposite effects on CREB phosphorylation because PP2B blockade prevented aldosterone-induced CREB phosphorylation without affecting the total amount of CREB, therefore excluding the possibilities of an increase in ubiquitination and the degradation of phosphorylated CREB.^[@CVQ379C22]^ In the heart, several isoforms of phosphodiesterase (PDE) hydrolyze cAMP and cGMP,^[@CVQ379C25]^ and the activities of these enzymes are modulated by phosphorylation.^[@CVQ379C26]^ Therefore, PP2B blockade may decrease CREB activation by inhibiting PDE dephosphorylation, thereby increasing PDE activity. Indeed, the inhibition of PDE4 was shown to elicit cAMP/protein kinase A-dependent CREB phosphorylation in cardiac cells.^[@CVQ379C27]^ A priori, our results differ from those describing an inhibitory effect of aldosterone-activated MRs on CREB phosphorylation through PP2B in vascular smooth muscle cells.^[@CVQ379C28]^ However, in cardiomyocytes, the response to aldosterone is mediated mostly by GRs and our results are thus consistent with the reported positive effect of dexamethasone-activated GRs on CREB signalling.^[@CVQ379C28]^

A cross-talk between *I*~CaT~ and CREB signalling is consistent with their opposite expression profiles, together with their antagonistic physiological functions. *I*~CaT~ and CREB signalling do not seem to be critical for normal cardiac function^[@CVQ379C8],[@CVQ379C29]^ but, in pathological conditions, CREB signalling was implicated in angiotensin II-induced hypertrophy.^[@CVQ379C30]^ Stenosis-induced hypertrophy showed an opposite pattern in terms of *I*~CaT~ re-emergence and CREB activation. Indeed, hypertrophied cardiomyocytes in the rat 6-week-stenosis model displayed an increase in phosphorylated CREB levels. The phosphorylation of CREB was almost abolished in the 12-week stenosis group and coincided with *I*~CaT~ re-emergence. In addition, when the re-emergence of *I*~CaT~ is reversed, the decrease in *I*~CaT~ density is correlated with a re-increase in phosphorylated CREB protein levels. Therefore, the negative feedback of *I*~CaT~ on CREB signalling observed in neonatal cardiomyocytes also seems to occur in pathological conditions in the adult. This result also suggests that *I*~CaT~ signalling renders cardiomyocytes resistant to hypertrophic factor-induced CREB signalling in the later stages of cardiac hypertrophy. Thus, loss of the negative feedback regulation of CREB signalling by *I*~CaT~ may partly account for the hypersensitivity to hypertrophy described for Ca~v~3.1^−/−^ mice.^[@CVQ379C8]^

The CREB and *I*~CaT~-signalling pathways have opposite effects on cell proliferation. For example, *I*~CaT~ signalling and CREB signalling have antagonistic effect on the pathway mediated by cell-cycle inhibitor p21CIP1.^[@CVQ379C31]^ This feature is particularly important in heart, as recent study has reported the persistence in adolescent heart of immature cardiomyocytes with *I*~CaT~-generated Ca^2+^ influx.^[@CVQ379C32]^ The CREB and *I*~CaT~-signalling pathways also have opposite effects on cell-death processes. CREB signalling was presumed to have anti-apoptotic effects through the upregulation of Bcl-2^[@CVQ379C33]^ and the prevention of NO-induced apoptosis.^[@CVQ379C27]^ Conversely, the activities of PP2A and PP1 have been associated with cell apoptosis.^[@CVQ379C23]^ Our study shows that, in aldosterone-treated cardiomyocytes, *I*~CaT~-induced PP2A activation increases the expression of pro-apoptotic markers, such as caspase 9 and the Bcl-xS variant. Consistent with these findings, cardiomyocyte apoptosis was first detected 24 h after aldosterone exposure and the longer term (48 h) effects of aldosterone involve an increase in necrosis rather than apoptosis. The blockade of *I*~CaT~-generated Ca^2+^ signalling decreases cell death by reducing both apoptosis and necrosis, whereas, as previously reported,^[@CVQ379C34]^ the blockade of I~CaL~ decreases necrosis rather than apoptosis. Aldosterone therefore induces different signalling pathways through Ca^2+^ microdomains, related to either *I*~CaT~- or I~CaL~-generated Ca^2+^ influx, such as the activation of PP2A--PP1 or PP2B,^[@CVQ379C24]^ respectively, resulting in temporally regulated cell processes. Consistent with this idea, an increase in the levels of apoptotic markers in the pathological model was associated with the re-emergence of *I*~CaT~ in long-term stenosis ([Supplementary material online, *FigureS5*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq379/DC1)). Nevertheless, further investigation will be needed to confirm the relationship between PP2A and CREB dephosphorylation in adult rat during heart pathology.

In conclusion, the main finding of our study is that the increase in *I*~CaT~ density induces Ca^2+^ signalling, which targets PP2A--PP1 and results in a downregulation of CREB target genes such as those associated with cardiac hypertrophy. Through its targeting of PP2A--PP1, *I*~CaT~ increases pro-apoptotic markers and cell death. Although neonatal cardiomyocytes in culture do not completely reflect what takes place in the adult, we confirm that the re-emergence of *I*~CaT~ in a long-term cardiac hypertrophy model is associated with the reduction of CREB-mediated gene expression and the stimulation of expression of apoptotic markers. Thus, our results suggest that, during cardiac pathology, *I*~CaT~ may limit the progression of hypertrophy, thereby corroborating the conclusion of Nakayama *et al.*^[@CVQ379C8]^ Whether or not cell death induced by *I*~CaT~ has a 'protective' effect against heart disease, such as described by Nakayama *et al*., is difficult to reconcile and needs to be further investigated. However, it is noteworthy that the protective effect of *I*~CaT~ described by Nakayama *et al.* occurs via an NOS3-dependent signalling, the product of which was shown to result in cardiomyocyte apoptosis.^[@CVQ379C35]^ The *I*~CaT~/PP2A/CREB signalling pathway, described in this study, may represent an alternative to *I*~CaT~/NOS3/PKG1 signalling pathway involved in the anti-hypertrophic effect of *I*~CaT~ during heart pathology.

5.. Limitations {#s5}
===============

Most papers describing an effect of aldosterone on ionic currents in cardiomyocyte use a concentration of 1 µM aldosterone, and we found that 1 µM Aldo was indeed the most potent concentration for upregulating the promoter of the *cacna1g* gene. We should point out that 1 µM aldosterone is approximately two orders of magnitude higher than physiological concentration. However, *in vivo*, the impact of paracrine effects, such as those of the renin--angiotensin II--aldosterone system, which is thought to occur in the heart,^[@CVQ379C36]^ cannot be ignored. Such effects may locally increase aldosterone concentration and increase the impact of plasma aldosterone concentration.

Supplementary material {#s6}
======================

[Supplementary material is available at *Cardiovascular Research* online](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq379/DC1).
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